Skip to main content

Table 11 Neurological conditions

From: Benefits and harms of medical cannabis: a scoping review of systematic reviews

Author, year {refid} Search dates; # databases searched Funding source Nstudies Illness/condition Intervention/comparator Outcomes Conclusions from data AMSTAR-2 rating
Baldinger, 2012 [50] To Jan 2011 and Cochrane specialized register to Feb 14, 2011; 4 Non-profit 1 ALS/motor neuron disease I: Plant-derived cannabinoids
C: Placebo
• Muscle cramps
• Muscle cramps as AEs
No statistically significant difference between groups L
Gloss, 2014 [72] Searched on Sept 9, 2013; 6 NR 4 Epilepsy I: Plant-derived cannabinoids
C: placebo
• Seizure freedom for 12 months No studies assessed primary outcome in this review M
Krishnan, 2009 [59] Dec 2005–Apr 2008; 6 NR 1 Dementia I: Synthetic cannabinoids
C: Placebo
• Body weight
• Triceps skinfold thickness
• Disturbed behavior
• Affect
Only one study included L
Hanson, 2011 [74] Jan 1990 to Oct 2009; 5 Government 1 Dementia I: Synthetic cannabinoids
C: placebo
• Weight
• Negative affect
• Disruptive behavior
Only one study included L
CADTH, 2018 [83] Jan 1 2012 to Nov 29, 2017; 6 No funding 4 Dementia I: Plant-derived cannabinoids
C: Placebo
• Static balance
• Dynamic balance
• Stride length
• Total AEs
• Dizziness
• Somnolence
• Balance disorders
• Falls
• Severe AEs
Only one study included CL
  1. AE adverse effect, ALS amyotrophic lateral sclerosis, CADTH Canadian Agency for Drugs and Technologies in Health, NR not reported